We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Sanofi SNY announced that it has entered into a definitive agreement to acquire Blueprint Medicines BPMC for a total deal value of up to $9.5 billion. Following the announcement, shares of BPMC ...

The French pharmaceutical giant struck a deal to buy the Cambridge biotech for about $9.1 billion, or $129 per share. Blueprint’s (Nasdaq: BPMC) shares began trading at $103.17 apiece on Monday ...

The deal with Blueprint, a Cambridge, Mass.-based immunology-disease specialist, is set to give Sanofi ownership over both an approved drug and an early-stage immunology pipeline, the companies said.

Sanofi’s offer to purchase Blueprint includes a payment of $129.00 per share in cash, which is a 27% premium over Blueprint’s closing price on May 30, 2025.

France-based pharmaceutical company Sanofi stated Monday that it will acquire US-based Blueprint Medicines Corporation for $9.1 billion to expand its portfolio in rare immunological diseases.

LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company ...

In other recent news, Blueprint Medicines has reported a surprising first-quarter 2025 earnings per share of $0.01, significantly surpassing the forecasted -$0.49.

Sanofi SAN -1.02%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.04%increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...

Blueprint’s CEO, Kate Haviland, expressed pride in the company’s innovations and collaborations that have improved patient outcomes. She anticipates that the merger with Sanofi will accelerate their ...